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Peste des Petits Ruminants (PPR) is a viral disease affecting domestic and small
wild ruminants. Endemic in large parts of the world, PPR causes severe damages
to animal production and household economies. In 2015, FAO and OIE launched a
global eradication program (GCSE) based on vaccination campaigns. The success
of GCSE shall depend on the implementation of vaccination campaigns, accounting
for husbandry practices, mobility and the periodicity of small ruminants’ population
renewal. In Mauritania, PPR outbreaks occur annually despite ongoing annual vaccination
campaigns since 2008. Here, we developed a mathematical model to assess the impact
of four vaccination strategies (including the GSCE one), the importance of their timing of
implementation and the usefulness of individual animal identification on the reduction of
PPR burden. The model was calibrated on data collected through ad-hoc surveys about
demographic dynamics, disease impact, and national seroprevalence using Monte Carlo
Markov Chain procedure. Numerical simulations were used to estimate the number of
averted deaths over the next 12 years. The model results showed that the GSCE strategy
prevented the largest number of deaths (9.2 million vs. 6.2 for random strategy) and
provided one of the highest economic returns among all strategies (Benefit-Cost Ratio
around 16 vs. 7 for random strategy). According to its current cost, identification would
be a viable investment that could reduce the number of vaccine doses to distribute by
20–60%. Whilst the implementation of the identification system is crucial for PPR control,
its success depends also on a coordinated approach at the regional level.
Keywords: PPR, West Africa, mathematical modeling, vaccination, cost-benefit analysis, global strategy for
control and eradication (GSCE)
INTRODUCTION
Peste des Petits Ruminants (PPR) is a viral infectious disease affecting domestic (goats and sheep)
and small wild ruminants (1, 2). The virus can infect camels (3–5), cattle, and buffalos (3, 6)
although their role in the transmission remains unclear. PPR virus (PPRV) is transmitted through
close contact between infected and susceptible animals. Common signs of the infection are high
fever, ocular and nasal discharges, erosive lesions on different mucous membranes, particularly in
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the mouth, diarrhea and respiratory distress. Because these
symptoms are similar to those of other diseases such as
rinderpest, pasteurellosis, and bluetongue (7), the clinical
diagnosis is taken as provisional until confirmed by a laboratory.
Depending on age and species (sheep are clinically more resistant
than goats) the disease may be hyper-acute (mortality at 98%
among 4–7 months old animals), acute (mortality at 60% among
all population), mild (no mortality), or sub-clinical (8, 9). The
sub-clinical form is frequent in Sahelian ruminants, in particular
among sheep: the infected animal, although not showing any
clinical signs, may shed the virus and transmit it to other animals
by close contact (10).
Due to the severe impact of PPR on animal production,
and following the successful rinderpest eradication, FAO and
OIE have developed a strategy for PPR eradication by 2030
relying on vaccination campaigns and disease surveillance (11).
Indeed, as for rinderpest, there are a very efficacious attenuated
PPR vaccines that provides lifelong immunity and efficient
PPR specific diagnostic tools for disease surveillance (12–15).
Despite the similarities with rinderpest, the PPR eradication
strategy should take account of some characteristics of small
ruminant production that could hinder the process: the small
ruminants population is much larger and grows faster than that
of cattle; small ruminants have a lower socio-economic value
and consequently less investments are made for their health;
small ruminants can be sold more easily to cover household
needs, and can be traded in large flocks (16). The PPR Global
Strategy for the Control and Eradication (GSCE) is composed of
4 necessary steps: 1-Assessment, 2-Control, 3-Eradication, and
4-Post-eradication follow-up (11). In stage 2, mass vaccination
(100%) of all animals older than 3 months of age is suggested
in a first phase, followed by a phase of targeted vaccination of
animals between 4 and 12 months of age. Previous work (16)
has shown that, at worldwide level, the eradication programme
would be highly beneficial economically, with an average benefit-
cost ratio of 33.8, providing a compelling argument for PPR
eradication. On the other hand, other works (17–19) showed
that other costs, like the logistic (fuel for vehicles, maintenance
of the cold chain etc.) and the personnel (time and missions to
vaccinate animals) ones, and the vaccine wastage (doses given to
already vaccinated animals) could have a relevant impact on the
vaccination campaign, accounting for, in some cases, up to 70%
of the campaign costs. To be effective, GSCE should be tailored
to country epidemiological situation and take account of small
ruminants production system dynamics.
Small ruminant production plays a major role in Mauritania
economy. Indeed, goat and sheep production ensures (an almost)
self-sufficiency for the country’s red meat consumption and their
trade represents a major source of income contributing to almost
70% of the agricultural GDP1. PPR is endemic in Mauritania,
with outbreaks reported yearly during winter time (January-
March) and during the Tabaski period2.
1GDP, Gross Domestic Product.
2Tabaski is theMuslim religious festivity of Aid-el-Kebir, during which each family
sacrifices a sheep. The date of tabaski depends on the lunar calendar and every year
is anticipated of 11 days.
Livestock mobility and population turnover are two of the
main factors contributing to the propagation and persistence of
the virus in the Sahelian region (20, 21). In West Africa, animals,
mainly adult ones, are moved in search of better grazing areas
(i.e., transhumance) (21–23), to be sold alive at markets (i.e., for
commercial reasons and at religious festivities such as Tabaski)
(24, 25), or to be exchanged among families and relatives (i.e.,
confiage) (25, 26). Because of these movements, infected and
susceptible (e.g., naïve) herds can get in contact, thus allowing
virus transmission.
On the other hand, population renewal sustains endemicity
of the virus. Depending on husbandry practices and agro-
ecological systems, births are concentrated in 1 or 2 periods of
the year. Newborn animals from mothers with PPR antibodies
(i.e., naturally immunized or vaccinated), can inherit maternal
antibodies, through colostrum, and be protected from the
infection for the first 2–4 months of their life. After this period,
animals become fully susceptible to PPR (27, 28) thus ensuring
the regular re-introduction in the population of fully susceptible
animals that could feed the disease cycle (29).
PPR represents a huge constraint to the development of
Mauritania, affecting the economies of middle-low incomes
families. Symptomatic animals are treated with antibiotics for
a week (30) and vitamins. These treatments are done at the
disease onset, aiming to prevent secondary bacterial infection,
reduce severity of the disease and minimize economic losses. A
retrospective study in Mauritania. El Arbi (10) reported that the
practice of giving antibiotics to animals is widespread among
herders and livestock owners, although this is not recommended
by OIE. Vaccination remains the only viable and practical tool
to control the disease as it will be impossible to implement
drastic sanitary measures, stamping out policy and restriction of
animal movements in Mauritania. Small ruminants vaccination
campaigns against PPR are implemented since 2008 but the
coverage rate remains low (ranging from 2 to 8% between 2008
and 2010; and in 2018 reaching 15.6% of the population) (10).
The low vaccination coverage can be explained by several factors,
such as: (i) vaccination is not compulsory, except in case of
outbreaks; (ii) there is a lack of information about vaccine
benefits (10), and most importantly, (iii) logistics issues, such
as the cold chain for maintaining the vaccine, constrain the
distribution of the vaccines. Nevertheless, for small ruminants’
owners, vaccinating an animal costs 0.10 USD against 1.40 USD
for giving antibiotics treatment (10).
To stop the epidemics spreading the GSCE (11) requires the
post-vaccination immunity coverage to reach at least 70% (PVIR
threshold), 80% to consider the country PPR-free. The PVIR
threshold depends on the basic reproduction ratio R0 that could
vary depending on the characteristics of the geographical area
and epidemic setting. For example, the authors of Fournié et al.
(31) estimated a lower value of the PVIR threshold, around
61.7% for the Ethiopian small ruminant population. Moreover, as
shown in Hammami et al. (29, 32) for sub-Saharan Africa herds,
the immunity coverage is strongly dependent on the month
of vaccination.
Effective and efficient use of public funds is considered
as necessary in the context of limited resource availability.
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In the Mauritanian context, the economic evaluation of PPR
eradication scenario options through a cost-benefit analysis is
therefore of great interest as it would inform the government
about the most cost-effective choice, at community level, between
financing of the vaccination campaign and the management
of disease outbreaks by breeders. In this work, we used a
dynamic model to estimate the impact of PPR in Mauritania
and economic benefits of different vaccination strategies, some
of them already being in place, others to be implemented, for
the period 2018–2030. Based on recent epidemiological and
socio-economic data collected on the field, our model takes
account of both transmission and demographic dynamics of the
Mauritanian national herd. Dynamical models are commonly
used in human and animal health, and have been applied to
study cost-effectiveness or cost benefits of vaccination strategies
(33–35) mainly for their capacity of assessing indirect effects
of vaccination (36, 37). A similar model was developed for the
Ethiopian national herd (31). We also used the model to assess
if and under which conditions identification and “identification
and screening” could be viable procedures to reduce the number
of vaccine doses to distribute by minimizing vaccination wastage.
MATERIALS AND METHODS
Study Area
Mauritania is located on the African Atlantic coast, confining
with Morocco, Western Sahara, Algeria, Mali, and Senegal.
The northern part of the country is hyper arid, while the
rest is arid (38). The country is divided in 15 Wilayas (i.e.,
regions), subdivided in 44 Moughataas (departments). Most
of the population is concentrated along the coast, mainly in
Nouakchott accounting for almost a quarter of the population,
and along the river Senegal in the South. In 2016, Mauritanian
small ruminant national population counts around 6.2 million
goats and 9.6 million sheep (http://www.fao.org/faostat/), mostly
located in the Eastern (50% of national herd) and Southern
(35%) Wilayas along the Senegal River. According to the recent
demographic survey done by ONARDEL3 and Mauritanian
Veterinary Services, small ruminant herds are mixed (sheep
and goats) with a higher proportion of sheep, reaching 70% of
the herd.
The first documented occurrence of PPR dates back to 1982
in the Gorgol Wilaya (39). Since then, the disease has been
considered endemic in the country. According to the 2010 PPR
national serosurvey, conducted under the frame of the AU-
Ibar project VACNADA (http://www.au-ibar.org/vacnada), the
estimated seroprevalence rate among small ruminants was 39%
(95% C.I. 37–41%) (40).
Data
Data on herd demography, PPR seroprevalence and disease
impact were collected by ONARDEL officers through ad-hoc
national surveys to calibrate the epidemiological model. Data
3ONARDEL (Office National de Recherche et Développement de l’Elevage), it is
the competent body for animal health in Mauritania
on herd demography, which include deaths, births, purchases,
and sales of small ruminants were collected in 2015 through a
survey among all the Wilayas, except the Nouakchott district
(investigated Wilayas are the colored ones in Figure 1). During
the same year, a retrospective study was conducted to retrieve
information on the impact of PPR outbreaks, number of cases
and deaths, in the 12 previous months. The study was done in 10
Wilayas located in the three major pastoral areas of Mauritania:
Hods, Assaba, and Senegal River valley (patterned Wilayas in
Figure 1). Finally, in 2010 a national serosurvey campaign was
conducted as part of the VACNADA project activities to estimate
PPR prevalence in 10 Wilayas (circles in Figure 1).
Demographic Data
A total of 2,892 small ruminant herds were surveyed among 12
Wilayas in the pastoral area. Information were collected about
herd size, their composition in terms of sex (male and female),
species (goats and sheep) and age (weans, younger than 6months,
and animals older than 6 months), and the demographic events
which had occurred over the previous 12 months (births and
deaths, animal entry and exit, see Table 1).
Serological Data
Sheep and goats older than 3months and coming from 21 villages
in 10 Wilayas were sampled for a total of 1,897 small ruminants
(711 goats and 1,186 sheep). The collected sera were tested for
the presence of IgG antibodies against PPRV. For each animal,
information about species, sex, and age (based on teeth counting)
were also collected. The results show a significant difference
according to species, with sheep presenting a higher prevalence
level than goats (Table 2).
Disease Impact Data
Seven hundred and eight herders were surveyed using a semi-
structured questionnaire over the events of the last 12 months,
in particular: PPR knowledge; PPR cases and related deaths in
the herd; intervention costs and the impact of the disease on
the animal production, and epidemiological and economic data
collected for more than 9,200 animals. Herders were chosen
according to husbandry practices: transhumant or sedentary.
No distinction was made between species in the premises, their
gender and age. Table 3 reports some of the survey results that
have been used to calibrate the model. The fatality rate has been
evaluated as the ratio of PPR-related deaths over cases counted in
a year.
Model Structure and Calibration
The small ruminant population (sheep and goats) demographics
and transmission dynamics were simulated using a deterministic
age-stratified compartmental model, without differentiating
animals according to their species or their spatial location. A
pictorial representation of the model is given in Figure 2 (to
simplify, only the first and the i-th age-group are presented).
The model considered a population stratified in seven age-
groups (0–3 months-old, 3–6 months-old, 6–12 months-old,
12–24 months-old, 24–36 months-old, 36–48 months-old, and
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FIGURE 1 | Wilayas included in the demographic (color), impact (dotted pattern) and seroprevalence (circles of darker color and increasing size by positive
percentage) surveys.
TABLE 1 | Data from national demographic survey conducted in 2015.
Species Weans
(<6 months old)
Others Population Births
(last 12 months)
Entries Deaths
(last 12 months)
Exit
Goats 43,729 113,387 157,116 38,046 1,730 9,998 12,629
Sheep 287,869 107,975 395,844 97,814 7,114 36,673 43,973
Total 331,598 221,362 552,960 135,860 8,844 46,671 56,602
Entries and exits indicate the total number of animals entering or leaving the herd, respectively, due to purchases, sales, festivities and loans.
TABLE 2 | Number and percentage (in brackets) of seropositive PPR animals in each age group, by species.
Goats Sheep Small ruminants
Age (month) Population Positive (%) Population Positive (%) Population Positive (%)
3–6 16 6 (37.5) 34 9 (26.5) 50 15 (33.3)
6–12 136 44 (32.4) 233 102 (43.8) 369 146 (39.6)
12–24 156 58 (37.2) 285 117 (41.1) 441 175(39.7)
24–36 145 49 (33.8) 260 103 (39.6) 405 152 (37.5)
36–48 128 42 (32.8) 212 79 (37.3) 340 121 (35.6)
48+ 130 44 (33.9) 162 90 (55.6) 292 134 (45.9)
Total 711 243 (34.2) 1186 500 (42.2) 1897 743 (39.2)
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TABLE 3 | Summary table of disease impact survey by type of rearing.
Sedentary Transhumant Total
Herds 178 530 708
Population (n) 7,645 89,570 97,215
PPR Cases (z) 1,147 7,167 8,314
PPR-related Deaths 459 1,792 2,251
Fatality rate 40% 25% 27.0%
48 months and older), the age structure being fixed a priori
to match the age stratification of the serological survey. The
youngest age-group (0–3 months old) accounts for the fact
that a large fraction (around 92%) of newborn animals can
be protected from the disease over the first 3 months of their
life due to the potential inheritance of maternal antibodies
against PPRV (27, 29). Because of this, and only for the first
group, an extra compartment “Imm” is added to account for
animals protected by maternal antibodies. In each age-group,
susceptible animals (S) move to the latent state (E) after effective
contacts with infectious animals (I), and subsequently become
infectious (I). Infectious animals (I), after the infectious period,
may recover (R) with a probability (1-p), or die for disease
related causes (D) with a probability (p). The epidemiological
dynamics is coupled with the underlying demographic one, with
animals dying (with natural mortality rate µ), aging (with rate
ε), leaving or entering the population due to trade exchanges to
and from other countries (with rate outgoing and incoming), and
reproducing (with rate α). We supposed that only animals older
than 1 year could be exchanged and give birth. In Mauritania,
births are concentrated in two specific moments of the year
(August–September and December–January) and movements
of small ruminants are concentrated in two periods: between
April and June and around Tabaski (26) whose occurrence is
anticipated every year of 11 days. The Tabaski-related peak
of movements accounts for one fifth of the annual volume
of animals traded and outbreaks are reported during this
period. We adapted the transmission model to account for these
characteristics. The list of parameters and their values is shown
in Supplementary Table 2.
Demographic Parameters’ Estimation
We considered a disease-free population, where the population
in each age class (Na) was susceptible (no infected animal) to
study the demographic dynamics of the population. At each
time, each age class could change due to death, birth, aging, sale,
and purchase of animals. We calibrated the model to estimate
natural mortality, fertility, entry, and exit rates due to commercial
exchanges. We supposed that the mortality rate was the same
for all age groups (µ) except the last one (µ5). Fertility rate (α),
entry (incoming), and exit (outgoing) ones were null for the first
3 age groups, and constant for all the other. The rates (α,µ,µ5,
incoming, outgoing) were estimated by fitting model results to
data in Table 1 using a Bayesian Framework (41). The model ran
for a set of parameters to simulate the equivalent of 100 years,
with a time step of 1 day. At the equilibrium, we estimated the
proportion of deaths, births, entries and exits during the last 12
months, i.e.,
px =
x∑
a Na
Where x indicates the annual number of one of the
events (death, birth, entry and exit) as simulated by our
model. We sampled from the posterior distribution of the
parameters (α,µ,µ5, incoming, outgoing) using Metropolis-
Hastings algorithm, assuming uniform priors. The numbers of
deaths, births, entry and exits (nx) reported in demographic
survey data, Table 1, followed a binomial distribution.
nx ∼ Binom(Population, px)
Where Population is the number of small ruminants estimated
during the survey. We ran 50 independent chains of 1,000
iterations. Results of the calibration procedure are provided in
the Supplementary Material.
Transmission Model Calibration
Due to the age structure of the model, we introduced the
transmission matrix T whose elements Tij are the rate of
transmission from infected animals of age group j to susceptible
animals in age group i (42, 43). We imposed some transmission
patterns, to reduce the number of parameters to estimate.
Preliminary analysis of serological data showed that the
percentage of seropositive steadily increases for the age-groups
(3–6; 6–12 months) and subsequently flattens for older groups.
This indicates that the force of infection (λ), the rate at which the
susceptible population is infected changes drastically for animals
younger and older than 1 year of age: the bulk of infections occurs
among the youngest groups whilst new infections among the
oldest groups seldom occur. We assumed that:
{
Tij = β0 i, j = 1, 2, 3
Tij = β1 i, j = 4, 5, 6, 7
(1a, b)
with β1 ≪ β0. Elements in Equations (1a) and (1b) are the
matrix elements for the within-young (both i,j ≤ 3) and within-
old (both i,j > 3) groups, respectively, and correspond to the
block diagonal elements of the transmission matrix. The other
elements of the transmission matrix, indicating transmissions
between young (<1 year old) and old groups (>1 year old), we
impose to be equal to one of the two (β1 ,β0). We also considered
the case that the transmission parameter is constant across the
age groups (β1 = β0).
Symptoms appear after 4–6 days (31, 44–46), so we considered
an average latent period of 5 days, whilst death can occur after 5–
10 days from the onset of symptoms (9, 44, 45) and we considered
an infectious period of 5 days. The PPR-related mortality rate,
or fatality rate (p), varies with age. Young animals (3–12 months
old) are more likely to experience acute or super-acute infections
with fatality rate ranging from 70 to 100% (31, 47, 48). Among
older animals, more likely to experience a sub-acute form, the
fatality rate is negligible, and was set between 0 and 2%. Through
the calibration procedure, we estimated the values of the fatality
rates for the youngest age-groups.
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FIGURE 2 | Pictorial representation of the epidemiological model for the first and i-th age group.
The transmission parameters β1, β0 and the fatality rates
pinf, p0, for animals of age 0–3 months and 3–12 months,
respectively, were estimated through calibration by fitting the
model to serological and PPR-related death data in Tables 2, 3
and choosing the set of parameters minimizing the Deviance
Information Criterion (DIC) value (49). To calibrate the
transmission model, we consider that <1% of the population
was initially infectious and let the system run for 100 years. At
the equilibrium, we estimated, for each age-group the number of
recovered animals (Ra) and the total number of deaths caused by
the infection in the last year (D) among the infected animals in
the last year (Z). Parameters estimation was done by fitting the
fraction of the immune animals and the fraction of fatal cases to
the serological data of Table 2 and the fatal cases of Table 3.
{
pa = Ra/Na
pd = D/Z
(2a, b)
where Na is the population in the a-th age-group. The number
of seropositives (posa) and PPR-related deaths (deaths) follow a
binominal distribution:
{
posa = Bin(Na, pa)
deaths = Bin(Z, pd)
(3a, b)
For all forms of the transition matrix T, we ran 50 Markov chains
Monte Carlo (MCMC) Metropolis-Hastings algorithm of 1,000
iterations length and sampled from the posterior distribution of
the parameters Pars = (β1,β0, p0, pinf). The best model had the
lowest information criterion (DIC) (49) value. Results are shown
in Supplementary Table 2.
Forecasts and Impact of Four Different
Vaccination Strategies
Baseline Case and 16 Tested Scenarios
We initially run the baseline scenario, where no vaccination is
implemented. Then we considered 4 vaccination strategies that
could be applied for the period 2019–2030:
• National Strategy (SR): half of the population is vaccinated.
This is the current strategy implemented as a containment
measure inMauritania in case of appearance of new cases: only
half of the animals of herds in the vicinity of outbreaks herd
are vaccinated.
• Targeted scenario (ST): all animals between 4 and 12 months
of age are vaccinated. This is the strategy planned for the next
years in Mauritania.
• Mixed scenario (SM): National Strategy (SR) for the first 5
years, and targeted vaccination (ST) for the remaining years.
This scenario has been introduced to take account of the delay
for building up an identification system.
• Global Strategy for Control and Eradication (GSCE): all
animals older than 3 months are vaccinated during the first
2 years, followed by a targeted vaccination (ST) of animals
between 4 and 12 months until 2030. This is the procedure
recommended by the Global Strategy (11) to be implemented
for the first 4 years of the program.
For each strategy, the vaccination was implemented once a year
but simulated on four different months of the year (March, July,
October, and December), corresponding to specific demographic
events (before transhumance, before the first peak of births,
current period of vaccination, period around second peak of
births) and periods of population renewal. Delayed vaccination
could miss targeted population with long terms consequences
on the population health status. In total, we simulated 16
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different scenarios: 4 months of implementation for each of
the 4 strategies. In all scenarios, vaccine is given to animals
older than 3 months of age, since younger age animals might
be protected by maternal antibodies and still have an immature
immune system (11, 28). We also assumed that the vaccination is
fully successful (all the animals vaccinated end up immunized)
and confers a lifelong immunity. All scenarios start in 2018
with vaccination in October and 15.6% of animals vaccinated,
according to information provided by Veterinary Service. We
assessed the effectiveness of vaccination strategies by assuming
that the higher the cumulative number of cases/deaths averted,
the “better” the vaccination strategy. To further characterize the
benefits of the different strategies, we introduced the notion
of effective vaccine doses (E). Every year a certain quantity of
vaccine doses (Q) is administrated to small ruminant population.
Among them, due to the absence of an identification system,
certain number of doses is given to already immunized animals
either because they were previously vaccinated either because
have already experienced the disease. We indicated these doses
as wasted doses (W). The number of effective vaccine doses is the
quantity of vaccine that is given to susceptible animals:
E = Q−W (4)
The quantity of effective doses varies according to the strategy but
also depending on the period of the year and the health status of
the population.
Cost-Benefit Analysis
Disease-Related and Vaccination-Related Costs
Disease-related costs were distinguished from vaccination-
related ones. The former consists of only treatment expenses
(antibiotics+ vitamins) for each infected animal, incurred by the
owner. The treatment usually consists of antibiotics for 1 week
and vitamins and, in average, it amounts at ctr = 1.40$ for each
infected animal. Consequently, the total disease-related cost is
estimated as follow:
D = ctr ∗ Cases (5)
Two types of costs intervene in the cost of vaccination: the
public and the private contribution. Administrating a dose
of vaccine costs to the State cadm = 0.3$ including the
cost of the vaccine dose and logistic expenses, like the cold
chain, equipment, personnel and carburant. Each herder pays a
contribution of cpri = 0.1$ for each animal vaccinated. Therefore,
the vaccination-related costs can be estimated as follow:
V =
(
cadm + cpri
)
∗ Q = cV ∗ Q (6)
where cV =
(
cadm + cpri
)
is the total cost associated to each
vaccine dose.
A way to reduce vaccination costs is to reduce vaccine wastage
(W), consequently administering only the effective number of
doses (E). This can be achieved through individual identification
and screening of animals: identification will avoid vaccinating
animals that have been vaccinated during previous campaigns;
whilst screening will allow to identify animals that have already
experienced the disease and are already immunized. Excluding
those animals from vaccination will reduce the required number
of vaccine doses to administer the desired quantity of effective
doses (E). In this analysis we are interested in assessing the
viability and economical usefulness of the “identification and
screening” procedure.
Identification and screening come with costs. We considered
that animal identification is done during the vaccination.
Consequently, identified animals are also vaccinated ones. As
long as the cost of vaccinating all animals is higher than the
one of identifying and vaccinated only un-identified animals, the
identification is a viable cost:
cV ∗ Q ≥ (cV + cid) ∗ (Q−W) (7)
cid
cV + cid
≤
W
Q
(8)
Where the left side of Equation (7) corresponds to the cost of
vaccinating all the animals (identified and not) while the right
side corresponds to the cost of vaccinating (and identifying) only
the un-identified animals (Q-W).
Vaccine wastage can be further reduced by identifying and
vaccinating only the susceptible animals among un-identified
animals via an “identification and screening” procedure. We
consider that during the vaccination campaign, animals are
checked for identification marks: those already marked will
not be vaccinated, whilst the un-marked ones will be marked
and tested for the presence of PPR antibodies. Only those
animals with negative results will be vaccinated. A pictorial
representation for the “identification and screening procedure”
is given in Figure 3. Animals excluded from vaccination are
what we indicated with W, among them a fraction (1-p) is
already marked, from previous vaccination, and a fraction
p is seropositive. Besides the cost of dispensing doses, this
procedure should account for the costs of identifying animals and
screening. Some estimates of identification cost (cid) for animals
are already available and we are interested in estimating the
maximal acceptable cost for screening (cs). The “identification
and screening” procedure is economically advantageous until
its cost is < the cost of vaccinating all animals (cV
∗Q). This
condition can be expressed mathematically as:
cV ∗ Q ≥ (cV + cid + cs) (Q−W)+ (cid + cs) pW (9)
cs ≤
cV −
(
(cV + cid)∗(1−W/Q)+ cid∗p∗W/Q
)
p∗W/Q+ (1−W/Q)
(10)
The maximal cost depends on the fraction of seropositive as well
as the fraction of total wasted vaccine.
Benefits
The benefits evaluation involves two levels: the public and the
private one. In the first case, benefits are mostly indirect: because
of vaccination, less animals die from PPR and consequently
animal production increases together with related products
(milk, leather etc.). An increase in animal production means less
importation and avoiding currency weakening. At the same time,
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FIGURE 3 | Schematic representation of the cost evaluation for “identification and screening” procedure.
improvement of household socio-economic conditions due to
avoided mortality means higher taxes revenue. Private benefits
could be both direct and indirect. Through vaccination, owners
avoid medical expenses for treatments of infected animals.
Furthermore, more animals, in better health, can be sold at
markets increasing household income and providing some
means to face emergency. Furthermore, a higher income could
lead to improved social and health conditions of household
members. A schematic summary of benefits is presented
in Table 4.
Frontiers in Veterinary Science | www.frontiersin.org 8 July 2019 | Volume 6 | Article 242
ElArbi et al. PPR Control in Mauritania
TABLE 4 | Summary of direct and indirect benefits from vaccination.
Direct Indirect
Public N/A • Improve food security by
increasing animal production
• Taxes return
• Reduce import
• Avoid currency weakening
Private • Increase in animal
production
• Increase production of milk,
dairy products, and leather
• Higher revenue
• Avoid medical expenses to
treat infected animals
• Improve socio economic
status
• Improve health condition
In this analysis, we focus on direct benefits coming from
the avoided losses due to PPR related deaths (BS) and avoided
treatment expenses (BM) to assess the economic impact of the
vaccination. The market values of young and old animals are
different, with young ones, the more susceptible, sold at lower
price than older ones (ryoung < radult). The BS can be estimated
from the number of averted deaths in both groups as:
BS = ryoung ∗ YoungDeaths_Averted + radult ∗ AdultDeaths_Averted
(11)
Where YoungDeaths_Averted and AdultDeaths_Averted indicate
the number of PPR-related deaths averted in the young and adult
groups. The avoided treatment expenses (BM) can be estimated
from the number of cases prevented as
BM = ctr ∗ (YoungCases_Averted + AdultCases_Averted) (12)
Where YoungCases_Averted andAdultCases_Averted indicate the
number of PPR cases averted in the young and adult groups.
The total benefit can then be evaluated as:
BT = BS+ BM (13)
All the analysis, simulations, calibrations and plots were done
using the software R v 3.4.3 (50) and the packages deSolve (51),
fitR (52), and ggplot (53).
RESULTS
Calibration Results
Based on the lowest value of the DIC (49), the transmission
matrix optimizing the fit of the model can be written as:
T =


β0 β0 β0 β1 β1 β1 β1
β0 β0 β0 β1 β1 β1 β1
β0 β0 β0 β1 β1 β1 β1
β1 β1 β1 β1 β1 β1 β1
β1 β1 β1 β1 β1 β1 β1
β1 β1 β1 β1 β1 β1 β1
β1 β1 β1 β1 β1 β1 β1


where β1 < β0.
FIGURE 4 | Fatality rates and seroprevalence estimated over the calibration of
the transmission model. Dots represent the percentage of seropositive by age
group, and shaded red area indicates 50 and 95% confidence interval of
simulations. Inset shows the fatality rate estimate of the disease as from data
(dots) and model (blue boxplot).
The fraction of immunized animals by age group, estimated
by the model, matched well with sero-survey results (Figure 4)
especially in the youngest and oldest groups. Nevertheless, the
model predicts a slow increase of the seroprevalence with age, as
expected for an endemic disease, whilst data show a decrease in
the group between 3 and 4 years of age. The inset of Figure 4
shows the percentage of infected animals that subsequently die:
dots correspond to the estimate of the fatality rate from data
and the boxplot the estimates from the model. Despite the good
agreement on the serological aspects, the model predicts a higher
fatality rate relative to PPR (almost 10% above).
The calibration provided estimations for the demographic
and epidemiological parameters. We sampled from the posterior
distributions of the parameters to evaluate the basic reproductive
ratio R0 using the Next Generation Approach as in Diekmann
et al. (54). As reported in Supplementary Table 2, we found that
the median value of R0 is around 2.9 (95% C.I. between 2.7
and 3.35). Consequently, the fraction of animals that should be
vaccinated to reach the herd immunity threshold (HIT = 1 −
1/R0) is around 66% (95% C.I 64 and 71%).
Vaccination Scenarios
We simulated the evolution of the disease from 2018 until 2030
considering an initial population composed of 15.8million heads.
We sampled from the parameter’s distribution and for each
combination, we ran the model for 100 years to estimate the
equilibrium distribution of the population in the epidemiological
compartments. The equilibrium distribution has been used as the
initial state for all the simulation of the baseline (no vaccination)
and vaccination scenario.
Demographic and epidemiological results of simulations for
the baseline scenario, i.e., when no vaccination is considered
are illustrated in Figure 5, distinguishing animals of <1 year
of age (young) from the older ones (adult). The daily trend of
population is provided in Figure 5A, with peaks corresponding
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FIGURE 5 | Results from the baseline case. colors correspond to young (<1 year old) and adults (>1 year old), solid line corresponding of the median and shaded
area the 95% confidence interval of the simulations over a sample of 250 parameter values. Solid lines indicate the end/beginning of the year, while dashed line
indicates Tabaski date. (A) The population in each age group by day (B) the percentage of seropositive animals in each group (C) the number of new infections by day
(D) the cumulative number of PPR-related deaths by year.
to the two birthing periods. Population grows over time, almost
doubles in 10 years, following a trend similar to that predicted
by FAOStat. Figure 5B shows the yearly average percentage of
seropositive animals by age group. For adults the seroprevalence
is constant (43%, C.I.[42.6,43.2]) along the years, while it is
oscillating around the value (24.6 %, C.I[21,26.0]) for young. On
average, the total seroprevalence is around 39.2% C.I[38.3,39.7]),
comparable with the expected one from VACNADA data (10,
46). Figure 5C shows the daily number of new infections. The
epidemics show a recurrent pattern with a peak of new infections
occurring every year during the first few months, mostly among
young animals. Finally, Figure 5D shows the year-cumulative
number of PPR-related deaths. On average, every year, almost 2.5
million small ruminants would be affected by PPR and among
them almost 8.5 × 105 die of the disease. Few cases and deaths
were registered in the adult class.
Figure 6 shows the cumulative number of infections
(Figure 6A) and deaths (Figure 6B) averted along the 2019–2030
period by vaccination strategy (color) and month of vaccination
(plot). In 2018, the number of cases and deaths averted is
the same for all vaccination strategies, since we assumed the
same quantity of vaccine was distributed for all scenarios, and
accounted for around 2,700 infections and 650 deaths averted,
on average. Starting from 2019, the effects of the different
vaccination strategies are becoming distinct, and from 2020 we
can see two different trends: on one side the GSCE and targeted
(ST) strategies on the other the national strategy (SR) and the
mixed one (SM). GSCE-vaccination appears to be the most
effective strategy in terms of deaths and case reduction. The
difference between targeted strategy (ST) and GSCE is essentially
the vaccination coverage at the beginning, the latter considering
the double of vaccine doses. As expected, the mixed strategy’s
(SM) effects become more evident with time. Since the first 5
years there is no difference from a random vaccination, whilst
in the last few years the number of cases and deaths averted
increases. The gap in cases and deaths averted between the SR
and the GSCE strategy is that of a few million at the end (around
10 for the infections, and 3 for deaths). We notice that for each
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FIGURE 6 | Median cumulative number of cases (A) and deaths (B) averted by vaccination. Colors correspond to the vaccination strategy, while line type to the
month of vaccination. SR, National Strategy; ST, Targeted scenario; SM, Mixed scenario (SM) and GSCE, Global Strategy for Control and Eradication.
vaccination strategy there is a strong dependency on the month
of vaccination, with vaccination done in March and December
being the most effective ones.
Targeted vaccination (ST) is the most effective in terms of
doses distributed. In Figure 7 we report the quantity of vaccine
distributed (Q) each year according to the different strategy
and vaccination month, and the corresponding effective doses
(E). Each year of the simulation (position on the y-axis), for
each vaccination strategy (color) and month of implementation
(type of line), we draw a segment whose ends correspond to the
quantity of vaccine distributed (Q, right end) and the effective
one (E, on the left). The segment’s length quantifies the number
of wasted doses (W). As can be easily seen the quantity of doses
distributed each year by targeted and GSCE vaccination after
2020 is much smaller compared to a random allocation. However,
for the first 2 years the quantity of vaccine allocated according
to GSCE strategy is much higher than the others. Moreover, we
notice that the quantity of vaccine wasted (W) is much smaller
for targeted (ST) vaccination than any other vaccination strategy:
less vaccine is wasted. For the first 2 years of implementation,
the quantity of vaccine wasted for GSCE is higher than the other
allocations and in 2020 the quantity of vaccine wasted by the
GSCE strategy almost doubles. This is an effect of the previous
mass vaccination campaign. According to our model, vaccination
month has an effect on the quantity of vaccine to be distributed.
For targeted vaccination (ST), for example, vaccination in March
requires a slightly higher number of doses than for the other
months. This is due to the presence of animals born during the
second period of births, around December, which has become
eligible to be vaccinated (older than 3 months).
Costs and Benefits Analysis
Figure 8 shows, for each scenario, the cumulative costs of the
vaccination campaign (i.e., the cost of administrated? doses—
red line), the costs of the effective vaccination (i.e., the cost
of vaccinating only susceptible animals—blue line) and the
total benefit from the averted death and averted treatment
expenses (green line). For all scenarios, the estimated revenue
is around one order of magnitude higher than the cost for
vaccination. For SR strategies, independently of the month, the
cost of vaccination campaign is always increasing. Except for
vaccination implemented in March, for the SR case the benefits,
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FIGURE 7 | Quantity of vaccine distributed each year according to different
strategies (median). For each line, on the right the total number of doses
distributed, on the left the effective doses given to susceptible individuals. The
length of the rod corresponds to the number of doses wasted because given
to already infected individuals.
during the first years, are comparable to vaccination costs. For
ST strategies, effective and total vaccination costs (blue and
red line, respectively) are comparable, mainly due to the fact
that new born animals can be easily identified thus reducing
vaccine wastage, and are in all cases lower than those of SR.
The cumulative vaccination costs for ST monotonically increase
indicating that an (almost) fixed quantity of vaccines is used every
year. In the first 2 years, benefits suddenly increase. For the other
two strategies (SM and GSCE), the vaccination costs are slightly
higher than the targeted ones due to the massive vaccinations
at the beginning. For SM and CSCE strategies implemented in
months different from March, the benefits are comparable to the
costs and steadily increase in the first 2 years. For all strategies,
benefits from vaccination in March are immediately evident.
The total administration costs, the economic impact of
vaccine wastage and the costs for the effective vaccination at
the end of the period 2018–2030, together with the cumulative
benefits were summarized in Table 5. We indicate with BCR the
Benefit Cost Ratio, the amount of monetary gain realized by
a single vaccination dose. The random (not targeted) strategies
are the most expensive in terms of vaccine-administration costs
and vaccine wastage: the more vaccine doses are distributed
randomly, the more are wasted. Moreover, the benefits of SR
strategies are the lowest among all the strategies. Targeted
interventions, on the other hand, have the lowest administration
costs and wastage, and, at the same time, the highest fraction of
effective vaccination and economics benefit. The analysis of BCR
shows that ST strategies are the most effective, whilst SR are the
least ones. In Table 5, we identified in bold, for each strategy,
the most effective month of vaccination. The effectiveness is
estimated as the economic benefit by single dose distributed, as
an example 1 USD invested in SR strategy in December returns
7.15 USD more. For all strategies, the most effective month
of vaccination is March, except for the target one where it is
December. In terms of BCR vaccinating in March is the most
cost-effective period, except for ST, for whom December is the
best period.
For SR strategies, the percentage of vaccines wasted is between
62 and 66 % depending on the month of vaccination, whilst for
targeted strategies the figure lies between 20 and 35%, Reducing
the wastage, through animal identification, could further increase
the benefits. Identification cost (cid) amounts to 0.10$ per animal,
thus contributing to 20% of the cost for vaccinating and identify
animals (cid+ cV ) that is, in most of the cases (not for the target
strategies), less than the fraction of wastage. Finally, the estimated
maximal cost for the screening procedure (cs) according to the
scenario and percentage of seropositives in the population were
presented in Figure 9. The maximal screening cost (cs) depends
on the total vaccination cost (cV ), the PPR prevalence and also the
fraction of wastage. The latter two could change along the years.
For each strategy we have considered three periods (2018–2020;
2020–2025; 2025–2030) to take account of possible variations
in vaccine wastage. In Figure 9 each line corresponds to the
maximal screening cost for a specific value of the prevalence,
while the shaded areas correspond to the range of vaccination
wastage in the period. Intersection between the line and the
shaded area indicate the maximum affordable screening cost
for the period. A negative or null value of (cs) indicates that
identification screening procedure is not economically viable and
then not worthy implementing. We notice that the higher the
prevalence the lower is the maximal screening costs. For most
of the strategy the maximal screening cost varies between 0 and 1
USD, except for the ST that is almost null. Themaximal screening
costs for strategy, decrease during the three periods, except for
the SR strategy. In the late period for this strategy, the screening
option is still viable till a cost of 1 USD. This is mainly due to the
fact that SR strategy has the highest fraction of vaccine wasted.
For the SM strategy, we notice that during the second period the
vaccination wastage widely changes, due to switch from mass to
targeted vaccination.
DISCUSSION
PPR is a major constraint to small ruminant production in
Mauritania with serious negative impacts to the livelihoods of
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FIGURE 8 | Cumulative cost and benefit for each strategy (row) and month of vaccination. Green indicates benefits from averted mortality, red the vaccination cost,
and blue the loss due to wasted vaccination, all expressed in U.S. Dollars. Due to different scales of costs and benefit, estimates are given in Log10.
small farmer households. Several factors contribute to maintain
the disease endemic in the area, among them population renewal
and animal mobility. Safe and very effective vaccines are available
for the control of the disease, which is now targeted for global
eradication by year 2030. In this work, we presented a dynamical
model for the transmission of PPR in Mauritania. Our model
considers an undistinguished population of small ruminants,
divided by age group, and takes account of some demographic
factors (birth seasonality, movements, and renewal dynamics)
ruling small ruminants’ dynamics. Calibrated on serological data
collected during the 2010 national serosurvey campaign and
data from national surveys on herd’s demography and disease
impact, our model predicts a higher fatality rate for the disease
than estimated from the data (37% against 27% from data).
However, outbreaks investigations in three Wilayas during 2012
epidemics suggest a case-fatality rate close to our estimation
(range [39; 58]%) (40, 46). This discrepancy could be related to
the fact that estimation of PPR-related deaths wasn’t confirmed
by diagnostic control but based on surveyed recollection of
previous year’s PPR-related events. Due to this, the number of
cases or the number of deaths related to PPR could have been
easily miscalculated.
Our model predicts a value of R0 around 2.9, consequently
the PVIR threshold is fixed around 66.6% a value in-between
the GSCE PVIR estimate (70%) and those predicted by Fournié
et al. (31).
In the baseline scenario, where no vaccination is applied, the
model predicts around 16 million deaths due to PPR before
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TABLE 5 | Cumulative costs and benefits from the different vaccination scenario.
Vaccination Administration costs (million $) Effective doses (million $) Vaccination wasted (million $)
March Jul Oct Dec March Jul Oct Dec March Jul Oct Dec
SR 40.5 36.7 37.6 39.0 21.7 18.4 19.1 20.4 18.8 18.3 18.5 18.6
ST 16.9 13.1 13.4 14.9 14.3 9.7 10.6 12.5 2.6 3.4 2.8 2.4
SM 27.6 23.7 24.1 25.6 18.1 14.1 14.8 16.5 9.5 9.6 9.3 9.1
GSCE 27.3 23.7 24.1 25.5 18.9 15.0 15.9 17.5 8.4 8.7 8.2 8.0
Benefits BS (million $) BM (million $) BT = BS + BM (million $) (BCR = BT/cost)
March Jul Oct Dec March Jul Oct Dec March Jul Oct Dec
SR 264 166 171 211 25.5 18.5 19.3 22.1 289.9 (7.15) 184.5 (5.0) 190.3 (5.1) 231.1 (5.9)
ST 378 235 240 337 38.7 24.3 29.9 34.9 416.7 (24.6) 259.3 (19.4) 269.9 (20.1) 371.9 (24.9)
SM 326 212 240 284 32.7 22.7 25.8 29.5 358.7 (12.9) 234.7 (9.9) 265.8 (11.02) 313.5 (12.2)
GSCE 387 276 314 354 40.0 29.4 33.3 37.2 427 (15.6) 305.4 (12.9) 347.3 (14.4) 391.2 (15.3)
SR, National Strategy; ST, Targeted scenario; SM, Mixed scenario (SM) and GSCE, Global Strategy for Control and Eradication. Top part of the table Vaccination information; bottom
part benefits. Administration Costs indicate the total amount spent between 2018–2030, while Vaccination Wasted indicates the cost of the vaccine given to already vaccinated or
immunized animals, with Effective doses we indicated the total costs of vaccinating only susceptible animals. Benefits are classified as those related to the market value of the animals
(BS) and those related to the avoidance of medical treatments (BM). BT indicates the total benefit as the sum of the previous ones. Bold cells indicate those strategies with highest
Benefit cost ratio (in parenthesis).
2030. Four different vaccination strategies have been considered
and their implementation simulated in four different periods of
the year. The use of a dynamical model allowed us to monitor
the population distribution across the different epidemiological
compartments at each time step of the simulation, but also
to estimate the wastage of vaccine doses (W) due to re-
vaccination of animals and vaccination of naturally immunized
ones. Random strategies (SR) are the less effective in terms of
the number of vaccine doses distributed (Q), wastage (W), and
reduction of PPR-related deaths, whilst the GSCE strategies are,
in the long term, the most effective in terms of cases and deaths
reduction. Targeted strategies (ST) are the most convenient in
terms of doses distributed, effectiveness of vaccination (higher
ratio of effective vaccine doses), due to the targeting of young
and probably non-immunized animals. On the other hand, the
GSCE strategies, independently of the month, prevent the largest
number of cases and deaths. The targeted strategies and the
GSCE ones rely on the targeted vaccination of young animals,
thus reducing the number of doses to distribute. As pointed out
by Hammami et al. (32), it looks safer to implement at least
2 mass vaccination campaigns, firstly because GSCE strategy
provides highest reduction in deaths and cases; secondly a
mass vaccination could overcome the reticence of some herders.
Strategies involved partial mass vaccination, like SM and SR,
despite the large number of doses deemed less effective.
In terms of economic benefits, a GSCE strategy, independently
of the vaccination month, has a much higher economic return
compared to other strategies, whilst the target ones (ST) had
the lowest costs associated. The cumulative vaccination costs
for GSCE strategy, over the period 2018–2030, are higher
than other strategies, mainly because of the mass campaign
implemented at the beginning. Moreover, in this work we
have compared only the cost of vaccination against those of
administering antibiotics and vitamins, the common practice
among herders. In the long term the abuse of antibiotics
could lead to development of antimicrobial resistance with
catastrophic consequences. Vaccination campaigns should be
accompanied with sensibilization activities on the use/abuse
of antibiotics.
The strategy choice and its implementation month have
important effects on both costs and benefits at long term.
For all strategies, vaccination should be implemented those
months with highest presence of immunocompetent animals,
i.e., animals older than 3 months of age and in good shape. In
Mauritania these months correspond to the months of December
and March. The end of March marks the beginning of the
hot dry season, during which an animal’s body and health
conditions deteriorate, thus affecting their immune response, and
herders begin leaving for transhumance. In our model, for all
strategies, the best months for vaccinating animals are December
and March. For vaccination implemented in these months the
number of deaths and cases prevented and the BCR are the
highest. Our model considers that vaccination is implemented in
1 month only, whilst Veterinary Service takes around 6 months
to cover all the national territory (between October and April).
BCR values for vaccination campaigns implement in the period
December-March fluctuate between the two values reported in
this article. Consequently, implementing a vaccination campaign
in this period has the highest benefit. Mauritania encompasses
several climatic areas (from hyper-arid in the North, to sub-
humid in the South along the river Senegal) and demographic
trends and transhumance’s schedules depend on the natural
resources available along the year, and could vary between years.
To improve their efficacy and covering the largest fraction of
animals, the vaccination schedule should take account of the
resource availability in the different areas and prioritize those
areas where resources could be depleted earlier (mainly from the
north of the area). In our model we have considered that all
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FIGURE 9 | Maximal Screening cost per animal by vaccination strategy and period. X-axes correspond to the vaccine wastage, while y axis corresponds to maximal
screening cost, zero value indicating that the procedure is not convenient. Line colors correspond to the evaluation for different sero-prevalence values. Shaded areas
correspond to range of vaccination wastage in that period by vaccination strategy.
neighboring countries have implemented the same vaccination
strategy and the same vaccination coverage rate. Preliminary
study, not reported in this article, has shown that vaccination
coverage in neighboring countries could have a dramatic effect
on Mauritania’s national herd. We considered several scenarios
in which the percentage of vaccinated animals among imported
animals could vary from 0 (no vaccination) to 100% (all the
animals are vaccinated). Focusing on the GSCE scenarios, if
other countries are not implementing any vaccination campaign
(vaccination coverage = 0%), the number of PPR-related deaths
in Mauritania will be between 4 and 20% higher depending on
vaccination month. On the other hand, when imported animals
are all vaccinated (vaccination coverage = 100%) the number
of deaths drastically reduces to almost 0. Reaching this level of
vaccination coverage would be possible vaccinating animal at
the border.
The BCR estimated for GSCE strategies in our model
varies between 19.4 and 24.9 depending on the month of
implementation. These values are far from those predicted by
Jones et al. (16) (median 33.8 varying between 18.5 for low
mortality area and 60.0 for high ones), with the benefit for
treatment avoidance accounting for 10% of the total BCR.
The discrepancies between our estimates and Jones’ ones could
be imputed to the small ruminants’ market values used in
our model.
Reducing the vaccine wastage could increase the economic
benefits of vaccination. Vaccination wastage impacts the
vaccination costs for a percentage varying from 20% (ST
March) to 66.6% (SR in July). Wastage reduction can be
achieved through the identification of the animals to avoid
multiple vaccinations, a strategy recommended by FAO and
OIE and sought to be implemented by Mauritania Veterinary
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Services. Our analysis provided strong arguments in favor of
the identification procedure whose contribution to the final
vaccination cost (administration + identification cost) is around
20%. Identification might then be considered as a viable
option for all the strategies, in particular for the random ones.
For targeted strategies (ST) the fraction of wasted vaccine is
comparable to the contribution of identification to the total
costs. However, due to the high BCR, the identification should
be implemented. We also tested the possibility of adopting a
two stage procedure, “identification and screening,” to increase
the amount of effective vaccine doses and reduce the final
number of animals to vaccinate. The possibility of deploying
this type of procedure is hindered by many factors, among
them the knowledge of the actual epidemiological situation,
the type of vaccination strategy and the costs related to the
screening test. The maximal cost for screening cs depends
on the prevalence and the vaccination strategy. A low value
of cs indicates that the implementation of the screening is
not economically viable. In our cases we found that for
most of our scenario the identification screening is not a
viable solution. Moreover, depending on the particular test
used, results couldn’t be immediate thus complicating the
vaccination procedure.
In our model, logistic costs were not detailed. However,
considering that a single dose is 0.10 USD, almost 80% of
the vaccine costs (0.40 USD) are related to logistic expenses.
Mauritania geographical extension and the distribution of
supporting infrastructure for maintaining the vaccine cold chain,
constrain the number and the duration of field missions by
Veterinary Services. The use of a thermostable vaccine could
greatly reduce the logistic costs. Future studies should consider a
detailed description of the logistic costs as part of costs benefits
analysis of vaccination campaign as previously done for the
Senegalese case (17).
Our model includes some characteristics of the Mauritania
husbandry practices, like births and movement’s seasonality.
At one-year coarser temporal scale, the serological estimates
are comparable to collected data. However, the model fails to
predict the outbreaks occurring around Tabaski (reported by
veterinarian services). These outbreaks are related to the rapid
concentration of animals in urban areas, and the consequent
burst of transmission. A model including multiple patches
of population, linked by animal movements, could better
describe the spatio-temporal patterns of disease propagation and
reproduce the Tabaski peaks of infections.
In our model we have considered that GSCE strategy is
applied all along the period 2018–2030 a period longer than
suggested by OIE. Disrupting the vaccination could cause the
re-insurgence of PPR, due to the re-introduction of the virus
by transboundary movements, with catastrophic effects on small
ruminants’ production, as it has occurred in Morocco during
2016. Mauritanian commercial movements are mostly directed
toward neighboring countries and import accounts for only
2% of the volume of animal traded. Moreover, due to the
permeability of the borders and the lack of an integrated
control and surveillance system in the area, PPR cannot be
fully eradicated from Mauritania. In fact, because of these
transboundary movements, infected and susceptible animals
could be regularly introduced in Mauritania and re-ignite PPR
outbreaks. The severity of these outbreaks would depend on the
level of vaccination coverage of neighboring countries. Either
Eradication requires a coordinated action at regional level with all
countries in the region implementing vaccination policies aiming
at covering 70–80% of the population of small ruminants and/or
vaccinating imported animals at the border. In this case, this will
mean adding extra vaccine doses, equivalent to the fraction of
imported animals in Mauritania, for each vaccination campaign
and create structures (vaccination parks) for the administration
of the vaccine. Also, in this case to better assess the effect of
vaccination in different countries a spatially structured model is
required that takes in account the seasonality of mobility and the
diffusion of immune animals.
In our model we have considered PPRV as the only
pathogen circulating in the area and affecting small ruminant’s
production. However, other pathogens circulating in the region,
like Pasteurellosis, could resurge after PPR eradication and
disrupt the production chain. Because of this, PPR vaccination
should be done during a joint campaign against other viruses
and bacteria.
Results of our model suggests that vaccination campaigns
done following the GSCE guidelines coupled with identification
procedure could be an economically viable option to control
PPR in Mauritania. However, eradication can be achieved only
through a coordinate approach at regional level.
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